Phase 1/2
Promising Results in a Phase I/II Clinical Trial
The Phase 1/2 clinical trial was conducted on twelve terminal recurrent Glioblastoma Multiforme (GBM) patients at the Hadassah Ein Kerem Medical Center using the NADAV virus.
Phase I/II Clinical Trial for Recurrent Glioblastoma Multiforme
PROMISING
RESULTS
IV treatment
01
4 patients responded:
observable tumor shrinkage,
extended survival rate
02
1 responsive patient showed complete response
03
No patients showed significant side effects
PROMISING
RESULTS
IV treatment
4 patients responded:
observable tumor shrinkage,
extended survival rate
1 responsive patient showed complete response
No patients showed significant side effects
(A) Patient at baseline
(B) Stable disease at first follow-up
(C) Partial response (PR) at second follow-up
(D) PR at 20 weeks from start of viro-therapy
(E and F) Complete response at 25 and30 weeks from start of viro-therapy
NADAV Study Advantages
None of the patients developed any severe side effects demonstrating the high safety profile of the NADAV administration.
The high safety level of administration of NADAV IV, can lead to the treatment of related metastases from the primary tumor.